BioMarin Pharmaceuticals, Inc. (BMRN) Tops Q3 EPS by 14c
Tweet
Share
E-mailGet Alerts BMRN Hot Sheet
Price: $66.70 -1.45%
Financial Fact:
Research and development: 160.83M
Today's EPS Names:
BTTX, VAXX, ELYS, More
Financial Fact:
Research and development: 160.83M
Today's EPS Names:
BTTX, VAXX, ELYS, More
Join SI Premium – FREE
BioMarin Pharmaceuticals, Inc. (NASDAQ: BMRN) reported Q3 EPS of $0.04, $0.14 better than the analyst estimate of ($0.10). Revenue for the quarter came in at $113.4 million versus the consensus estimate of $113.2 million.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- BioMarin Pharmaceutical Inc. (BMRN) PT Lowered to $59 at H.C. Wainwright
- BioMarin to acquire Alesta Therapeutics for $275M upfront
- Marti Technologies (MRT) Misses Q2 EPS by 9c ; Offers Guidance
Create E-mail Alert Related Categories
EarningsSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
